Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3999602 | Urologic Oncology: Seminars and Original Investigations | 2015 | 7 Pages |
Abstract
D׳Amico low-risk patients did not have a homogeneous histology at RP. Especially, non-AS candidates were at a higher risk of either upgrading or upstaging at final pathology. Tumor involvement greater than 50% per core was the most powerful indicator of adverse pathology. Therefore, DʼAmico low-risk criteria are not safe enough to identify AS candidates.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Jonas M.D., Philipp M.D., Georg M.D., Lars M.D., Thorsten M.D., Sarah M.D., Corinna M.D., Stefan M.D., Till M.D., Stefan M.D., Guido M.D., Burkhard M.D., Katharina M.D., Derya M.D., Uwe M.D., Hartwig M.D., Markus M.D., Pierre I. M.D.,